Clinical Trials
11 trialsNCT00638898 2025-03-20
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Phase 1 Completed
NCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00623077 2017-12-05
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00003926 2017-11-29
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00002601 2017-03-03
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
City of Hope Medical Center
Phase 2 Completed
NCT00357396 2015-11-25
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02507076 2015-07-23
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Albert Einstein College of Medicine
Phase NA Withdrawn
NCT00003425 2013-04-26
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
University of Kentucky
Phase 1/2 Completed
NCT00004250 2013-01-16
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003081 2010-09-20
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00165139 2009-11-02
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed